ESTRO25

Lung Breakthroughs at ESTRO25

European Society for Radiotherapy and Oncology (ESTRO) shared a post on LinkedIn:

“Lung breakthroughs at ESTRO25!

From osimertinib after chemoradiation in unresectable EGFR-mutant NSCLC (LAURA trial) to SBRT dose precision and ctDNA insights post-SABR, the lung sessions delivered key updates on optimising treatment and tracking response.

Read the summary of selected lung sessions, featuring highlights from the proffered papers and poster discussions.”

More posts featuring ESTRO.